Aging Is a Stack of Failures. Mitochondria May Sit at the Center.

Aging research doesn't converge on a single cause, because there isn't one. Telomeres shorten. Stem cell populations exhaust their capacity to divide. Proteins misfold and accumulate. Each of these represents a distinct failure mode, unfolding at its own roughly predictable rate. Among these parallel processes, many cell biologists place mitochondrial decline closest to the center of the cascade, in part because energy production underlies nearly everything else a cell does.

The structural story centers on a specific lipid: cardiolipin. It forms the inner mitochondrial membrane, the folded surface where the electron transport chain physically operates to generate ATP. Cardiolipin is unique to mitochondria, and it carries an ironic vulnerability — it's highly susceptible to oxidative damage generated as a byproduct of the very energy production process it makes possible. Over decades, that self-inflicted damage accumulates, and the membrane the power plant depends on slowly degrades from the inside.

When cardiolipin degrades, the geometry of the electron transport chain breaks down. Protons leak across the membrane instead of driving ATP synthesis efficiently. Reactive oxygen species spill into the surrounding cell. At that point, the cell has a few options: repair the membrane, trigger mitophagy to clear the damaged mitochondrion entirely, or simply accumulate dysfunctional mitochondria over time. In aging tissue, the research suggests accumulation increasingly wins out over repair or clearance.

SS-31, also known as elamipretide, is a four-amino-acid peptide designed at Cornell by researcher Hazel Szeto in the early 2000s, built specifically to bind cardiolipin on the inner mitochondrial membrane and stabilize its structure — not to stimulate activity or send a signal, but to structurally protect what's already there. Clinical trials to date span mitochondrial myopathies, age-related macular degeneration, heart failure with preserved ejection fraction, and Barth syndrome — different diseases united by the same underlying pathology: failing mitochondria and damaged cardiolipin.

In ordinary healthy aging, the same process unfolds more gradually — muscle weakens, cognition slows, recovery from exertion takes longer. The classical framing treats this as simple entropy, an inevitable cost of running biological systems for decades. The newer framing, informed by cardiolipin-specific research, suggests a meaningful portion of it may be structurally addressable rather than simply inevitable.

Why this matters for tracking: if mitochondrial membrane integrity really does sit near the center of the aging cascade, then the markers that reflect it — recovery time, metabolic bloodwork, resting energy expenditure — are worth tracking consistently over years, not just checking once when something already feels off.